CRISPR Therapeutics (NASDAQ: CRSP) experienced a significant surge of over 200% from early 2020 to early 2021 due to optimism surrounding the approval of its gene editing therapy, Casgevy, for blood disorders. However, the stock has declined in recent years and remains down more than 60% from its 2021 peak, despite a modest rebound this year. Additionally, Casgevy has yet to generate substantial revenue for the company, raising questions about CRISPR Therapeutics’ future prospects.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
